SIGN UP: Learn the latest on the road ahead for a COVID-19 vaccine at our live event on October 5
Courtesy of Art Kaplan; Courtesy of William Haseltine; Courtesy of Maria Elena Bottazzi; Samantha Lee/Business Insider
Subscribe to Business Insider to RSVP to our live event.
Already a subscriber? You can sign up here.
Coronavirus vaccine research is moving fast. Keep up on the latest — and know what's coming ahead — with Business Insider's latest live webinar on October 5th at 2:00 p.m. ET.
Several candidates are now in the final stage of clinical testing, with the leading vaccines likely providing pivotal effectiveness results before the end of the year.
But in order to truly help society, a vaccine needs to be safe, effective, and widely available. How close are we to actually having a vaccine that people can get access to? And what does that mean for the future in society's fight against this pandemic?
Business Insider's healthcare reporter Andrew Dunn will discuss these topics and more in a fast-moving webinar covering the current state-of-play with coronavirus vaccines and what to expect for the next several months.
Dunn will talk with three leading vaccine experts: Maria Elena Bottazzi, co-director of Texas Children's Hospital Center for Vaccine Development and associate dean of Baylor College of Medicine's National School of Tropical Medicine, Art Caplan, a bioethicist and founding head of the Division of Medical Ethics at New York University School of Medicine, and Dr. William Haseltine, infectious-disease expert and chair and president of ACCESS Health International.
The panel will discuss what it takes to get a vaccine candidate across the finish line and what happens after that. Even with a safe and effective vaccine, drugmakers and governments will need to collaborate on plans for mass-production, fairly distributing the shot, and convincing the public to get vaccinated. Leading experts will weigh in on the latest challenges and how they are being tackled.
from Business Insider https://ift.tt/3kVYCw4
No comments